# A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)

> **NCT06797674** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MK-7602
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT06797674
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-10
- **Primary completion:** 2025-08-12
- **Final completion:** 2025-08-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06797674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06797674, "A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06797674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*